Tislelizumab combined with first-line chemotherapy produced longer-term overall survival in advanced esophageal squamous cell carcinoma, according to results from a randomized phase 3 trial with multiple years of follow-up. The study followed patients across three years, reporting sustained benefit for the combination versus chemotherapy alone. The findings add to the growing body of evidence that PD-1 blockade can deepen durability in gastrointestinal malignancies where responses can be transient with chemotherapy alone. The trial also supports continued evaluation of tislelizumab-based regimens in earlier lines and in biomarker-enriched populations. For clinicians and payers, the key takeaway is persistence of the survival signal beyond the initial efficacy window, a factor that often influences adoption decisions for oncology combinations.